AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Rocket Pharmaceuticals In... (RCKT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

10.93

0.01 (0.09%)

At close: Feb 20, 2025, 3:59 PM

10.76

-1.51%

After-hours: Feb 20, 2025, 05:58 PM EST

undefined% (undefined)

Bid	10.75
Market Cap	1.16B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.73
PE Ratio (ttm)	-4
Forward PE	n/a
Analyst	Buy

Ask	10.99
Volume	655,963
Avg. Volume (20D)	1,465,549
Open	10.91
Previous Close	10.92
Day's Range	10.76 - 11.09
52-Week Range	9.33 - 31.47
Beta	undefined

About RCKT

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 18, 2015

Employees 268

Stock Exchange NASDAQ

Ticker Symbol RCKT

Website https://rocketpharma.com

Full Company Profile

Analyst Forecast

According to 10 analyst ratings, the average rating for RCKT stock is "Buy." The 12-month stock price forecast is $51, which is an increase of 366.82% from the latest price.

Buy 90.00%

Hold 10.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Rocket Pharmaceuticals Inc. is scheduled to release its earnings on Mar 4, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

-2.38%

Rocket Pharmaceuticals shares are trading lower af... Unlock content with Pro Subscription

4 months ago

+8.27%

Rocket Pharmaceuticals shares are trading higher after Scotiabank initiated coverage on the stock with a Sector Outperform rating on the stock and announced a $50 price target.

News

1 week ago · seekingalpha.com

Rocket Pharma Is A Buy At These Prices With Promising Data

Rocket Pharmaceuticals, Inc.'s RP-L201 for LAD-I faces FDA rejection but shows promising data; potential approval could unlock a $350M market. RP-L102 for Fanconi Anemia and RP-A501 for Danon Disease ...

1 month ago · zacks.com

Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earni...

1 month ago · businesswire.com

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...

2 months ago · investopedia.com

Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'

Shares of Rocket Pharmaceuticals (RCKT) jumped 5.5% intraday Wednesday as Jefferies initiated coverage of the biotech company with a "buy" rating on optimism about the experimental drugs in its pipeli...

2 months ago · businesswire.com

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

2 months ago · marketbeat.com

3 Small-Cap Stocks That Are Ready to Rocket Higher

The Russell 2000 Index, often called the small-cap index, is up about 19.6% in 2024. Much of that gain has come in the last six months, and the clarity after the U.S. presidential election is stirring...

2 months ago · businesswire.com

Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference